nodes	percent_of_prediction	percent_of_DWPC	metapath
Nelarabine—hematologic cancer—muscle cancer	0.851	1	CtDrD
Nelarabine—DGUOK—smooth muscle tissue—muscle cancer	0.00295	0.0791	CbGeAlD
Nelarabine—DGUOK—renal system—muscle cancer	0.00284	0.0762	CbGeAlD
Nelarabine—DGUOK—cardiac atrium—muscle cancer	0.00254	0.0682	CbGeAlD
Nelarabine—DGUOK—tendon—muscle cancer	0.00222	0.0595	CbGeAlD
Nelarabine—DGUOK—bone marrow—muscle cancer	0.00215	0.0576	CbGeAlD
Nelarabine—DGUOK—vagina—muscle cancer	0.00206	0.0552	CbGeAlD
Nelarabine—POLA1—Vinblastine—Vincristine—muscle cancer	0.00205	0.776	CbGdCrCtD
Nelarabine—ADA—C-MYB transcription factor network—MYF6—muscle cancer	0.00195	0.12	CbGpPWpGaD
Nelarabine—DGUOK—head—muscle cancer	0.0019	0.051	CbGeAlD
Nelarabine—DGUOK—testis—muscle cancer	0.00184	0.0492	CbGeAlD
Nelarabine—ADA—renal system—muscle cancer	0.00163	0.0436	CbGeAlD
Nelarabine—DCK—embryo—muscle cancer	0.00143	0.0383	CbGeAlD
Nelarabine—POLA1—tendon—muscle cancer	0.00137	0.0367	CbGeAlD
Nelarabine—POLA1—bone marrow—muscle cancer	0.00132	0.0355	CbGeAlD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—TP63—muscle cancer	0.0013	0.0803	CbGpPWpGaD
Nelarabine—POLA1—vagina—muscle cancer	0.00127	0.034	CbGeAlD
Nelarabine—ADA—tendon—muscle cancer	0.00127	0.034	CbGeAlD
Nelarabine—ADA—bone marrow—muscle cancer	0.00123	0.033	CbGeAlD
Nelarabine—ADA—vagina—muscle cancer	0.00118	0.0316	CbGeAlD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—TP63—muscle cancer	0.00116	0.0718	CbGpPWpGaD
Nelarabine—POLA1—testis—muscle cancer	0.00113	0.0304	CbGeAlD
Nelarabine—ADA—head—muscle cancer	0.00109	0.0292	CbGeAlD
Nelarabine—POLA1—E2F transcription factor network—TFE3—muscle cancer	0.00106	0.0656	CbGpPWpGaD
Nelarabine—ADA—testis—muscle cancer	0.00105	0.0282	CbGeAlD
Nelarabine—ADA—p73 transcription factor network—TP73—muscle cancer	0.000998	0.0616	CbGpPWpGaD
Nelarabine—DCK—cardiac atrium—muscle cancer	0.000967	0.0259	CbGeAlD
Nelarabine—ADA—p73 transcription factor network—TP63—muscle cancer	0.000858	0.053	CbGpPWpGaD
Nelarabine—DCK—tendon—muscle cancer	0.000843	0.0226	CbGeAlD
Nelarabine—DCK—bone marrow—muscle cancer	0.000817	0.0219	CbGeAlD
Nelarabine—DCK—vagina—muscle cancer	0.000782	0.021	CbGeAlD
Nelarabine—ADA—C-MYB transcription factor network—CD34—muscle cancer	0.000775	0.0478	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—MYOD1—muscle cancer	0.000775	0.0478	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—WT1—muscle cancer	0.000757	0.0467	CbGpPWpGaD
Nelarabine—DCK—head—muscle cancer	0.000723	0.0194	CbGeAlD
Nelarabine—POLA1—E2F transcription factor network—TP73—muscle cancer	0.000718	0.0443	CbGpPWpGaD
Nelarabine—DCK—testis—muscle cancer	0.000698	0.0187	CbGeAlD
Nelarabine—DCK—Epirubicin—Doxorubicin—muscle cancer	0.000592	0.224	CbGdCrCtD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—muscle cancer	0.000383	0.0236	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—MDM2—muscle cancer	0.000371	0.0229	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—FH—muscle cancer	0.000364	0.0225	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN2A—muscle cancer	0.000343	0.0212	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—MDM2—muscle cancer	0.000332	0.0205	CbGpPWpGaD
Nelarabine—ADA—C-MYB transcription factor network—KIT—muscle cancer	0.000296	0.0183	CbGpPWpGaD
Nelarabine—Dysarthria—Methotrexate—muscle cancer	0.000266	0.00288	CcSEcCtD
Nelarabine—Petechiae—Doxorubicin—muscle cancer	0.000265	0.00287	CcSEcCtD
Nelarabine—Chills—Dactinomycin—muscle cancer	0.000262	0.00283	CcSEcCtD
Nelarabine—Blood disorder—Doxorubicin—muscle cancer	0.000261	0.00283	CcSEcCtD
Nelarabine—Hypoaesthesia—Vincristine—muscle cancer	0.00026	0.00281	CcSEcCtD
Nelarabine—Urinary tract disorder—Vincristine—muscle cancer	0.000258	0.00279	CcSEcCtD
Nelarabine—Blood uric acid increased—Methotrexate—muscle cancer	0.000257	0.00278	CcSEcCtD
Nelarabine—Connective tissue disorder—Vincristine—muscle cancer	0.000256	0.00277	CcSEcCtD
Nelarabine—Urethral disorder—Vincristine—muscle cancer	0.000256	0.00277	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000252	0.0156	CbGpPWpGaD
Nelarabine—Neutropenia—Etoposide—muscle cancer	0.000247	0.00267	CcSEcCtD
Nelarabine—ADA—p73 transcription factor network—MDM2—muscle cancer	0.000245	0.0151	CbGpPWpGaD
Nelarabine—Depressed level of consciousness—Methotrexate—muscle cancer	0.000243	0.00263	CcSEcCtD
Nelarabine—Cardiac disorder—Vincristine—muscle cancer	0.000242	0.00262	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—CDKN2A—muscle cancer	0.000241	0.0149	CbGpPWpGaD
Nelarabine—Hyperbilirubinaemia—Doxorubicin—muscle cancer	0.00024	0.0026	CcSEcCtD
Nelarabine—Hypocalcaemia—Doxorubicin—muscle cancer	0.000238	0.00258	CcSEcCtD
Nelarabine—Pneumonia—Etoposide—muscle cancer	0.000237	0.00256	CcSEcCtD
Nelarabine—Angiopathy—Vincristine—muscle cancer	0.000237	0.00256	CcSEcCtD
Nelarabine—Infestation NOS—Etoposide—muscle cancer	0.000235	0.00255	CcSEcCtD
Nelarabine—Infestation—Etoposide—muscle cancer	0.000235	0.00255	CcSEcCtD
Nelarabine—Hyperuricaemia—Doxorubicin—muscle cancer	0.000235	0.00255	CcSEcCtD
Nelarabine—Mediastinal disorder—Vincristine—muscle cancer	0.000235	0.00254	CcSEcCtD
Nelarabine—Anaemia—Dactinomycin—muscle cancer	0.000235	0.00254	CcSEcCtD
Nelarabine—Blood bilirubin increased—Doxorubicin—muscle cancer	0.000231	0.0025	CcSEcCtD
Nelarabine—Dysarthria—Doxorubicin—muscle cancer	0.000231	0.0025	CcSEcCtD
Nelarabine—Neuropathy peripheral—Etoposide—muscle cancer	0.000231	0.0025	CcSEcCtD
Nelarabine—Coma—Methotrexate—muscle cancer	0.00023	0.00249	CcSEcCtD
Nelarabine—Stomatitis—Etoposide—muscle cancer	0.000229	0.00248	CcSEcCtD
Nelarabine—Mental disorder—Vincristine—muscle cancer	0.000229	0.00247	CcSEcCtD
Nelarabine—Neoplasm—Methotrexate—muscle cancer	0.000228	0.00247	CcSEcCtD
Nelarabine—Leukopenia—Dactinomycin—muscle cancer	0.000228	0.00246	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—PTGS2—muscle cancer	0.000225	0.0139	CbGpPWpGaD
Nelarabine—Gait disturbance—Doxorubicin—muscle cancer	0.000224	0.00242	CcSEcCtD
Nelarabine—Hepatobiliary disease—Etoposide—muscle cancer	0.000223	0.00241	CcSEcCtD
Nelarabine—Blood uric acid increased—Doxorubicin—muscle cancer	0.000222	0.0024	CcSEcCtD
Nelarabine—Coordination abnormal—Doxorubicin—muscle cancer	0.000222	0.0024	CcSEcCtD
Nelarabine—Back pain—Vincristine—muscle cancer	0.00022	0.00238	CcSEcCtD
Nelarabine—Sepsis—Methotrexate—muscle cancer	0.000219	0.00237	CcSEcCtD
Nelarabine—Myalgia—Dactinomycin—muscle cancer	0.000216	0.00234	CcSEcCtD
Nelarabine—Hypoaesthesia—Etoposide—muscle cancer	0.00021	0.00227	CcSEcCtD
Nelarabine—Anaemia—Vincristine—muscle cancer	0.00021	0.00227	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	0.000209	0.0129	CbGpPWpGaD
Nelarabine—Urinary tract disorder—Etoposide—muscle cancer	0.000209	0.00226	CcSEcCtD
Nelarabine—Oedema—Dactinomycin—muscle cancer	0.000207	0.00224	CcSEcCtD
Nelarabine—Urethral disorder—Etoposide—muscle cancer	0.000207	0.00224	CcSEcCtD
Nelarabine—Infection—Dactinomycin—muscle cancer	0.000206	0.00223	CcSEcCtD
Nelarabine—DGUOK—Metabolism—MED12—muscle cancer	0.000206	0.0127	CbGpPWpGaD
Nelarabine—Neuropathy—Doxorubicin—muscle cancer	0.000205	0.00222	CcSEcCtD
Nelarabine—Leukopenia—Vincristine—muscle cancer	0.000203	0.0022	CcSEcCtD
Nelarabine—Thrombocytopenia—Dactinomycin—muscle cancer	0.000203	0.0022	CcSEcCtD
Nelarabine—Coma—Doxorubicin—muscle cancer	0.000199	0.00216	CcSEcCtD
Nelarabine—Anorexia—Dactinomycin—muscle cancer	0.000198	0.00214	CcSEcCtD
Nelarabine—Eye disorder—Etoposide—muscle cancer	0.000197	0.00214	CcSEcCtD
Nelarabine—Neoplasm—Doxorubicin—muscle cancer	0.000197	0.00213	CcSEcCtD
Nelarabine—Convulsion—Vincristine—muscle cancer	0.000197	0.00213	CcSEcCtD
Nelarabine—Cardiac disorder—Etoposide—muscle cancer	0.000196	0.00212	CcSEcCtD
Nelarabine—Myalgia—Vincristine—muscle cancer	0.000193	0.00209	CcSEcCtD
Nelarabine—Angiopathy—Etoposide—muscle cancer	0.000192	0.00207	CcSEcCtD
Nelarabine—Hypertonia—Doxorubicin—muscle cancer	0.000191	0.00207	CcSEcCtD
Nelarabine—Mediastinal disorder—Etoposide—muscle cancer	0.00019	0.00206	CcSEcCtD
Nelarabine—Chills—Etoposide—muscle cancer	0.00019	0.00205	CcSEcCtD
Nelarabine—Mental disability—Doxorubicin—muscle cancer	0.000189	0.00205	CcSEcCtD
Nelarabine—Sepsis—Doxorubicin—muscle cancer	0.000189	0.00205	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000189	0.00204	CcSEcCtD
Nelarabine—DGUOK—Metabolism—ENO2—muscle cancer	0.000188	0.0116	CbGpPWpGaD
Nelarabine—Lethargy—Methotrexate—muscle cancer	0.000187	0.00202	CcSEcCtD
Nelarabine—Oedema—Vincristine—muscle cancer	0.000185	0.00201	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000184	0.0114	CbGpPWpGaD
Nelarabine—Infection—Vincristine—muscle cancer	0.000184	0.00199	CcSEcCtD
Nelarabine—Osteoarthritis—Methotrexate—muscle cancer	0.000183	0.00198	CcSEcCtD
Nelarabine—POLA1—E2F transcription factor network—CDKN2A—muscle cancer	0.000182	0.0112	CbGpPWpGaD
Nelarabine—Nervous system disorder—Vincristine—muscle cancer	0.000182	0.00197	CcSEcCtD
Nelarabine—Thrombocytopenia—Vincristine—muscle cancer	0.000181	0.00196	CcSEcCtD
Nelarabine—Decreased appetite—Dactinomycin—muscle cancer	0.00018	0.00195	CcSEcCtD
Nelarabine—Dysgeusia—Etoposide—muscle cancer	0.00018	0.00195	CcSEcCtD
Nelarabine—Fatigue—Dactinomycin—muscle cancer	0.000179	0.00193	CcSEcCtD
Nelarabine—Back pain—Etoposide—muscle cancer	0.000178	0.00193	CcSEcCtD
Nelarabine—Pain—Dactinomycin—muscle cancer	0.000177	0.00192	CcSEcCtD
Nelarabine—Anorexia—Vincristine—muscle cancer	0.000177	0.00191	CcSEcCtD
Nelarabine—Hypotension—Vincristine—muscle cancer	0.000173	0.00187	CcSEcCtD
Nelarabine—Ataxia—Methotrexate—muscle cancer	0.000172	0.00186	CcSEcCtD
Nelarabine—Feeling abnormal—Dactinomycin—muscle cancer	0.000171	0.00185	CcSEcCtD
Nelarabine—Anaemia—Etoposide—muscle cancer	0.00017	0.00184	CcSEcCtD
Nelarabine—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00017	0.00184	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000169	0.00183	CcSEcCtD
Nelarabine—Insomnia—Vincristine—muscle cancer	0.000168	0.00181	CcSEcCtD
Nelarabine—Paraesthesia—Vincristine—muscle cancer	0.000166	0.0018	CcSEcCtD
Nelarabine—Leukopenia—Etoposide—muscle cancer	0.000165	0.00178	CcSEcCtD
Nelarabine—Body temperature increased—Dactinomycin—muscle cancer	0.000164	0.00177	CcSEcCtD
Nelarabine—Abdominal pain—Dactinomycin—muscle cancer	0.000164	0.00177	CcSEcCtD
Nelarabine—Hypoglycaemia—Doxorubicin—muscle cancer	0.000162	0.00176	CcSEcCtD
Nelarabine—Loss of consciousness—Etoposide—muscle cancer	0.000162	0.00175	CcSEcCtD
Nelarabine—Lethargy—Doxorubicin—muscle cancer	0.000162	0.00175	CcSEcCtD
Nelarabine—Decreased appetite—Vincristine—muscle cancer	0.000161	0.00174	CcSEcCtD
Nelarabine—Cough—Etoposide—muscle cancer	0.000161	0.00174	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Vincristine—muscle cancer	0.00016	0.00173	CcSEcCtD
Nelarabine—Fatigue—Vincristine—muscle cancer	0.00016	0.00173	CcSEcCtD
Nelarabine—Convulsion—Etoposide—muscle cancer	0.000159	0.00172	CcSEcCtD
Nelarabine—Constipation—Vincristine—muscle cancer	0.000158	0.00171	CcSEcCtD
Nelarabine—Pain—Vincristine—muscle cancer	0.000158	0.00171	CcSEcCtD
Nelarabine—Pain in extremity—Doxorubicin—muscle cancer	0.000158	0.00171	CcSEcCtD
Nelarabine—Osteoarthritis—Doxorubicin—muscle cancer	0.000158	0.00171	CcSEcCtD
Nelarabine—Chest pain—Etoposide—muscle cancer	0.000157	0.00169	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	0.000153	0.00946	CbGpPWpGaD
Nelarabine—Gastrointestinal pain—Vincristine—muscle cancer	0.000152	0.00164	CcSEcCtD
Nelarabine—Confusional state—Etoposide—muscle cancer	0.000151	0.00164	CcSEcCtD
Nelarabine—Infection—Etoposide—muscle cancer	0.000149	0.00161	CcSEcCtD
Nelarabine—Ataxia—Doxorubicin—muscle cancer	0.000149	0.00161	CcSEcCtD
Nelarabine—Asthenia—Dactinomycin—muscle cancer	0.000149	0.00161	CcSEcCtD
Nelarabine—Blood creatinine increased—Doxorubicin—muscle cancer	0.000148	0.00161	CcSEcCtD
Nelarabine—Neutropenia—Methotrexate—muscle cancer	0.000148	0.0016	CcSEcCtD
Nelarabine—Dehydration—Doxorubicin—muscle cancer	0.000147	0.00159	CcSEcCtD
Nelarabine—Thrombocytopenia—Etoposide—muscle cancer	0.000147	0.00159	CcSEcCtD
Nelarabine—Body temperature increased—Vincristine—muscle cancer	0.000147	0.00159	CcSEcCtD
Nelarabine—Abdominal pain—Vincristine—muscle cancer	0.000147	0.00159	CcSEcCtD
Nelarabine—Hypokalaemia—Doxorubicin—muscle cancer	0.000144	0.00156	CcSEcCtD
Nelarabine—Anorexia—Etoposide—muscle cancer	0.000143	0.00155	CcSEcCtD
Nelarabine—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000143	0.00154	CcSEcCtD
Nelarabine—Diarrhoea—Dactinomycin—muscle cancer	0.000142	0.00154	CcSEcCtD
Nelarabine—Pneumonia—Methotrexate—muscle cancer	0.000142	0.00153	CcSEcCtD
Nelarabine—Infestation NOS—Methotrexate—muscle cancer	0.000141	0.00153	CcSEcCtD
Nelarabine—Infestation—Methotrexate—muscle cancer	0.000141	0.00153	CcSEcCtD
Nelarabine—Depression—Methotrexate—muscle cancer	0.000141	0.00152	CcSEcCtD
Nelarabine—Hypotension—Etoposide—muscle cancer	0.00014	0.00152	CcSEcCtD
Nelarabine—Muscular weakness—Doxorubicin—muscle cancer	0.00014	0.00151	CcSEcCtD
Nelarabine—Abdominal distension—Doxorubicin—muscle cancer	0.000138	0.00149	CcSEcCtD
Nelarabine—Stomatitis—Methotrexate—muscle cancer	0.000137	0.00149	CcSEcCtD
Nelarabine—Paraesthesia—Etoposide—muscle cancer	0.000135	0.00146	CcSEcCtD
Nelarabine—Dyspnoea—Etoposide—muscle cancer	0.000134	0.00145	CcSEcCtD
Nelarabine—Somnolence—Etoposide—muscle cancer	0.000133	0.00144	CcSEcCtD
Nelarabine—Hepatobiliary disease—Methotrexate—muscle cancer	0.000133	0.00144	CcSEcCtD
Nelarabine—Epistaxis—Methotrexate—muscle cancer	0.000133	0.00144	CcSEcCtD
Nelarabine—Asthenia—Vincristine—muscle cancer	0.000133	0.00144	CcSEcCtD
Nelarabine—Vomiting—Dactinomycin—muscle cancer	0.000132	0.00143	CcSEcCtD
Nelarabine—Decreased appetite—Etoposide—muscle cancer	0.000131	0.00141	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Etoposide—muscle cancer	0.00013	0.0014	CcSEcCtD
Nelarabine—Fatigue—Etoposide—muscle cancer	0.000129	0.0014	CcSEcCtD
Nelarabine—Constipation—Etoposide—muscle cancer	0.000128	0.00139	CcSEcCtD
Nelarabine—Pain—Etoposide—muscle cancer	0.000128	0.00139	CcSEcCtD
Nelarabine—Neutropenia—Doxorubicin—muscle cancer	0.000128	0.00139	CcSEcCtD
Nelarabine—Diarrhoea—Vincristine—muscle cancer	0.000127	0.00137	CcSEcCtD
Nelarabine—Urinary tract disorder—Methotrexate—muscle cancer	0.000125	0.00135	CcSEcCtD
Nelarabine—Urethral disorder—Methotrexate—muscle cancer	0.000124	0.00134	CcSEcCtD
Nelarabine—Feeling abnormal—Etoposide—muscle cancer	0.000124	0.00134	CcSEcCtD
Nelarabine—Hyperglycaemia—Doxorubicin—muscle cancer	0.000124	0.00134	CcSEcCtD
Nelarabine—Nausea—Dactinomycin—muscle cancer	0.000123	0.00133	CcSEcCtD
Nelarabine—Pneumonia—Doxorubicin—muscle cancer	0.000123	0.00133	CcSEcCtD
Nelarabine—Gastrointestinal pain—Etoposide—muscle cancer	0.000123	0.00133	CcSEcCtD
Nelarabine—Dizziness—Vincristine—muscle cancer	0.000123	0.00133	CcSEcCtD
Nelarabine—Infestation NOS—Doxorubicin—muscle cancer	0.000122	0.00132	CcSEcCtD
Nelarabine—Infestation—Doxorubicin—muscle cancer	0.000122	0.00132	CcSEcCtD
Nelarabine—ADA—Metabolism—FH—muscle cancer	0.000121	0.00746	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	0.00012	0.00742	CbGpPWpGaD
Nelarabine—Neuropathy peripheral—Doxorubicin—muscle cancer	0.00012	0.00129	CcSEcCtD
Nelarabine—POLA1—Mitotic M-M/G1 phases—BUB1B—muscle cancer	0.000119	0.00737	CbGpPWpGaD
Nelarabine—Stomatitis—Doxorubicin—muscle cancer	0.000119	0.00129	CcSEcCtD
Nelarabine—Body temperature increased—Etoposide—muscle cancer	0.000119	0.00128	CcSEcCtD
Nelarabine—Abdominal pain—Etoposide—muscle cancer	0.000119	0.00128	CcSEcCtD
Nelarabine—Eye disorder—Methotrexate—muscle cancer	0.000118	0.00128	CcSEcCtD
Nelarabine—Vomiting—Vincristine—muscle cancer	0.000118	0.00127	CcSEcCtD
Nelarabine—Cardiac disorder—Methotrexate—muscle cancer	0.000117	0.00127	CcSEcCtD
Nelarabine—Headache—Vincristine—muscle cancer	0.000116	0.00126	CcSEcCtD
Nelarabine—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000115	0.00125	CcSEcCtD
Nelarabine—Epistaxis—Doxorubicin—muscle cancer	0.000115	0.00125	CcSEcCtD
Nelarabine—Angiopathy—Methotrexate—muscle cancer	0.000115	0.00124	CcSEcCtD
Nelarabine—Sinusitis—Doxorubicin—muscle cancer	0.000115	0.00124	CcSEcCtD
Nelarabine—Mediastinal disorder—Methotrexate—muscle cancer	0.000114	0.00123	CcSEcCtD
Nelarabine—Chills—Methotrexate—muscle cancer	0.000114	0.00123	CcSEcCtD
Nelarabine—DCK—Metabolism—FH—muscle cancer	0.000112	0.00689	CbGpPWpGaD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CDKN2A—muscle cancer	0.000111	0.00687	CbGpPWpGaD
Nelarabine—Mental disorder—Methotrexate—muscle cancer	0.000111	0.0012	CcSEcCtD
Nelarabine—Malnutrition—Methotrexate—muscle cancer	0.00011	0.00119	CcSEcCtD
Nelarabine—Nausea—Vincristine—muscle cancer	0.00011	0.00119	CcSEcCtD
Nelarabine—Hypoaesthesia—Doxorubicin—muscle cancer	0.000109	0.00118	CcSEcCtD
Nelarabine—Urinary tract disorder—Doxorubicin—muscle cancer	0.000108	0.00117	CcSEcCtD
Nelarabine—Oedema peripheral—Doxorubicin—muscle cancer	0.000108	0.00117	CcSEcCtD
Nelarabine—Dysgeusia—Methotrexate—muscle cancer	0.000108	0.00117	CcSEcCtD
Nelarabine—Asthenia—Etoposide—muscle cancer	0.000108	0.00117	CcSEcCtD
Nelarabine—Connective tissue disorder—Doxorubicin—muscle cancer	0.000108	0.00117	CcSEcCtD
Nelarabine—Urethral disorder—Doxorubicin—muscle cancer	0.000107	0.00116	CcSEcCtD
Nelarabine—Back pain—Methotrexate—muscle cancer	0.000107	0.00115	CcSEcCtD
Nelarabine—Vision blurred—Methotrexate—muscle cancer	0.000104	0.00112	CcSEcCtD
Nelarabine—Diarrhoea—Etoposide—muscle cancer	0.000103	0.00111	CcSEcCtD
Nelarabine—Eye disorder—Doxorubicin—muscle cancer	0.000102	0.00111	CcSEcCtD
Nelarabine—Anaemia—Methotrexate—muscle cancer	0.000102	0.0011	CcSEcCtD
Nelarabine—Cardiac disorder—Doxorubicin—muscle cancer	0.000102	0.0011	CcSEcCtD
Nelarabine—Angiopathy—Doxorubicin—muscle cancer	9.94e-05	0.00108	CcSEcCtD
Nelarabine—Dizziness—Etoposide—muscle cancer	9.93e-05	0.00107	CcSEcCtD
Nelarabine—Mediastinal disorder—Doxorubicin—muscle cancer	9.88e-05	0.00107	CcSEcCtD
Nelarabine—Leukopenia—Methotrexate—muscle cancer	9.86e-05	0.00107	CcSEcCtD
Nelarabine—Chills—Doxorubicin—muscle cancer	9.83e-05	0.00106	CcSEcCtD
Nelarabine—Cough—Methotrexate—muscle cancer	9.61e-05	0.00104	CcSEcCtD
Nelarabine—Mental disorder—Doxorubicin—muscle cancer	9.6e-05	0.00104	CcSEcCtD
Nelarabine—Convulsion—Methotrexate—muscle cancer	9.55e-05	0.00103	CcSEcCtD
Nelarabine—Vomiting—Etoposide—muscle cancer	9.55e-05	0.00103	CcSEcCtD
Nelarabine—Malnutrition—Doxorubicin—muscle cancer	9.54e-05	0.00103	CcSEcCtD
Nelarabine—Headache—Etoposide—muscle cancer	9.4e-05	0.00102	CcSEcCtD
Nelarabine—Arthralgia—Methotrexate—muscle cancer	9.38e-05	0.00101	CcSEcCtD
Nelarabine—Chest pain—Methotrexate—muscle cancer	9.38e-05	0.00101	CcSEcCtD
Nelarabine—Myalgia—Methotrexate—muscle cancer	9.38e-05	0.00101	CcSEcCtD
Nelarabine—Dysgeusia—Doxorubicin—muscle cancer	9.34e-05	0.00101	CcSEcCtD
Nelarabine—Back pain—Doxorubicin—muscle cancer	9.23e-05	0.000998	CcSEcCtD
Nelarabine—Confusional state—Methotrexate—muscle cancer	9.07e-05	0.000981	CcSEcCtD
Nelarabine—Vision blurred—Doxorubicin—muscle cancer	8.99e-05	0.000973	CcSEcCtD
Nelarabine—Infection—Methotrexate—muscle cancer	8.93e-05	0.000967	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—BUB1B—muscle cancer	8.93e-05	0.00551	CbGpPWpGaD
Nelarabine—Nausea—Etoposide—muscle cancer	8.92e-05	0.000965	CcSEcCtD
Nelarabine—Nervous system disorder—Methotrexate—muscle cancer	8.82e-05	0.000954	CcSEcCtD
Nelarabine—Anaemia—Doxorubicin—muscle cancer	8.82e-05	0.000954	CcSEcCtD
Nelarabine—Thrombocytopenia—Methotrexate—muscle cancer	8.8e-05	0.000953	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	8.8e-05	0.00543	CbGpPWpGaD
Nelarabine—Anorexia—Methotrexate—muscle cancer	8.57e-05	0.000927	CcSEcCtD
Nelarabine—Leukopenia—Doxorubicin—muscle cancer	8.54e-05	0.000924	CcSEcCtD
Nelarabine—Hypotension—Methotrexate—muscle cancer	8.4e-05	0.000909	CcSEcCtD
Nelarabine—Loss of consciousness—Doxorubicin—muscle cancer	8.39e-05	0.000907	CcSEcCtD
Nelarabine—Cough—Doxorubicin—muscle cancer	8.33e-05	0.000901	CcSEcCtD
Nelarabine—Convulsion—Doxorubicin—muscle cancer	8.27e-05	0.000894	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Methotrexate—muscle cancer	8.19e-05	0.000886	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	8.17e-05	0.00504	CbGpPWpGaD
Nelarabine—Insomnia—Methotrexate—muscle cancer	8.13e-05	0.00088	CcSEcCtD
Nelarabine—Myalgia—Doxorubicin—muscle cancer	8.12e-05	0.000879	CcSEcCtD
Nelarabine—Chest pain—Doxorubicin—muscle cancer	8.12e-05	0.000879	CcSEcCtD
Nelarabine—Arthralgia—Doxorubicin—muscle cancer	8.12e-05	0.000879	CcSEcCtD
Nelarabine—Paraesthesia—Methotrexate—muscle cancer	8.07e-05	0.000874	CcSEcCtD
Nelarabine—Dyspnoea—Methotrexate—muscle cancer	8.02e-05	0.000867	CcSEcCtD
Nelarabine—Somnolence—Methotrexate—muscle cancer	7.99e-05	0.000865	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—BUB1B—muscle cancer	7.98e-05	0.00493	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	7.88e-05	0.00486	CbGpPWpGaD
Nelarabine—Confusional state—Doxorubicin—muscle cancer	7.85e-05	0.000849	CcSEcCtD
Nelarabine—Decreased appetite—Methotrexate—muscle cancer	7.82e-05	0.000846	CcSEcCtD
Nelarabine—Oedema—Doxorubicin—muscle cancer	7.79e-05	0.000842	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Methotrexate—muscle cancer	7.76e-05	0.00084	CcSEcCtD
Nelarabine—Fatigue—Methotrexate—muscle cancer	7.75e-05	0.000839	CcSEcCtD
Nelarabine—Infection—Doxorubicin—muscle cancer	7.74e-05	0.000837	CcSEcCtD
Nelarabine—Pain—Methotrexate—muscle cancer	7.69e-05	0.000832	CcSEcCtD
Nelarabine—Nervous system disorder—Doxorubicin—muscle cancer	7.64e-05	0.000826	CcSEcCtD
Nelarabine—Thrombocytopenia—Doxorubicin—muscle cancer	7.62e-05	0.000825	CcSEcCtD
Nelarabine—Anorexia—Doxorubicin—muscle cancer	7.42e-05	0.000803	CcSEcCtD
Nelarabine—Feeling abnormal—Methotrexate—muscle cancer	7.41e-05	0.000802	CcSEcCtD
Nelarabine—Gastrointestinal pain—Methotrexate—muscle cancer	7.35e-05	0.000796	CcSEcCtD
Nelarabine—Hypotension—Doxorubicin—muscle cancer	7.28e-05	0.000787	CcSEcCtD
Nelarabine—Abdominal pain—Methotrexate—muscle cancer	7.11e-05	0.000769	CcSEcCtD
Nelarabine—Body temperature increased—Methotrexate—muscle cancer	7.11e-05	0.000769	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Doxorubicin—muscle cancer	7.09e-05	0.000768	CcSEcCtD
Nelarabine—Insomnia—Doxorubicin—muscle cancer	7.04e-05	0.000762	CcSEcCtD
Nelarabine—Paraesthesia—Doxorubicin—muscle cancer	6.99e-05	0.000756	CcSEcCtD
Nelarabine—Dyspnoea—Doxorubicin—muscle cancer	6.94e-05	0.000751	CcSEcCtD
Nelarabine—Somnolence—Doxorubicin—muscle cancer	6.92e-05	0.000749	CcSEcCtD
Nelarabine—ADA—Metabolism—MED12—muscle cancer	6.83e-05	0.00422	CbGpPWpGaD
Nelarabine—Decreased appetite—Doxorubicin—muscle cancer	6.77e-05	0.000732	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Doxorubicin—muscle cancer	6.72e-05	0.000727	CcSEcCtD
Nelarabine—Fatigue—Doxorubicin—muscle cancer	6.71e-05	0.000726	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—TP53—muscle cancer	6.66e-05	0.00411	CbGpPWpGaD
Nelarabine—Constipation—Doxorubicin—muscle cancer	6.66e-05	0.00072	CcSEcCtD
Nelarabine—Pain—Doxorubicin—muscle cancer	6.66e-05	0.00072	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PTGS2—muscle cancer	6.53e-05	0.00403	CbGpPWpGaD
Nelarabine—Asthenia—Methotrexate—muscle cancer	6.45e-05	0.000698	CcSEcCtD
Nelarabine—Feeling abnormal—Doxorubicin—muscle cancer	6.42e-05	0.000694	CcSEcCtD
Nelarabine—Gastrointestinal pain—Doxorubicin—muscle cancer	6.37e-05	0.000689	CcSEcCtD
Nelarabine—DCK—Metabolism—MED12—muscle cancer	6.3e-05	0.00389	CbGpPWpGaD
Nelarabine—ADA—Metabolism—ENO2—muscle cancer	6.23e-05	0.00384	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	6.21e-05	0.00383	CbGpPWpGaD
Nelarabine—Body temperature increased—Doxorubicin—muscle cancer	6.16e-05	0.000666	CcSEcCtD
Nelarabine—Abdominal pain—Doxorubicin—muscle cancer	6.16e-05	0.000666	CcSEcCtD
Nelarabine—Diarrhoea—Methotrexate—muscle cancer	6.15e-05	0.000666	CcSEcCtD
Nelarabine—Dizziness—Methotrexate—muscle cancer	5.95e-05	0.000643	CcSEcCtD
Nelarabine—DCK—Metabolism—ENO2—muscle cancer	5.75e-05	0.00355	CbGpPWpGaD
Nelarabine—Vomiting—Methotrexate—muscle cancer	5.72e-05	0.000619	CcSEcCtD
Nelarabine—Headache—Methotrexate—muscle cancer	5.63e-05	0.000609	CcSEcCtD
Nelarabine—Asthenia—Doxorubicin—muscle cancer	5.59e-05	0.000604	CcSEcCtD
Nelarabine—Nausea—Methotrexate—muscle cancer	5.34e-05	0.000578	CcSEcCtD
Nelarabine—Diarrhoea—Doxorubicin—muscle cancer	5.33e-05	0.000576	CcSEcCtD
Nelarabine—Dizziness—Doxorubicin—muscle cancer	5.15e-05	0.000557	CcSEcCtD
Nelarabine—Vomiting—Doxorubicin—muscle cancer	4.95e-05	0.000536	CcSEcCtD
Nelarabine—Headache—Doxorubicin—muscle cancer	4.88e-05	0.000528	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	4.69e-05	0.00289	CbGpPWpGaD
Nelarabine—Nausea—Doxorubicin—muscle cancer	4.63e-05	0.0005	CcSEcCtD
Nelarabine—POLA1—Cell Cycle, Mitotic—CDKN2A—muscle cancer	4.08e-05	0.00252	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CDKN2A—muscle cancer	3.65e-05	0.00225	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—MDM2—muscle cancer	3.54e-05	0.00218	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PTGS2—muscle cancer	2.17e-05	0.00134	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—TP53—muscle cancer	2.03e-05	0.00125	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PTGS2—muscle cancer	2e-05	0.00124	CbGpPWpGaD
